On-chip in vitro cell-network pre-clinical cardiac toxicity using spatiotemporal human cardiomyocyte measurement on a chip

Scientific Reports

Volumn 4, Issue , 2014, Pages

  Kaneko, Tomoyuki ^a,e   Nomura, Fumimasa ^a   Hamada, Tomoyo ^a   Abe, Yasuyuki ^b   Takamori, Hideo ^b   Sakakura, Tomoko ^b   Takasuna, Kiyoshi ^b   Sanbuissho, Atsushi ^b   Hyllner, Johan ^c,d   Sartipy, Peter ^d   Yasuda, Kenji ^a  

^a TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^b DAIICHI SANKYO CO   (Japan)

^c LINKÖPING UNIVERSITY   (Sweden)

^d Arvid Wallgrens Backe 20   (Sweden)

^e HOSEI UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CARDIOTOXICITY; CELL COMMUNICATION; CULTURE TECHNIQUE; DRUG EFFECTS; DRUG SCREENING; HEART MUSCLE CELL; HUMAN; IN VITRO STUDY; LAB ON A CHIP; METABOLISM; MICROCHIP ANALYSIS;

CARDIOTOXICITY; CELL COMMUNICATION; CELL CULTURE TECHNIQUES; DRUG EVALUATION, PRECLINICAL; HUMANS; IN VITRO TECHNIQUES; LAB-ON-A-CHIP DEVICES; MICROCHIP ANALYTICAL PROCEDURES; MYOCYTES, CARDIAC;

EID: 84899101781     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep04670     Document Type: Article

References (31)

1. Lawrence, C. L., Pollard, C. E., Hammond, T. G. & Valentin, J. P. In vitro models of proarrhythmia. Br. J. Pharmacol. 154, 1516-1522, doi:10.1038/bjp.2008.195 (2008).
2. Polak, S., Wiśniowska, B. & Brandys, J. Collation, assessment and analysis of literature in vitro data on hERG receptor blocking potency for subsequent modeling of drugs' cardiotoxic properties. J Appl Toxicol. 29, 183-206 (2009).
3. Olson, H. et al. Concordance of the toxicity of pharmaceuticals in humans and in animals. Regul. Toxicol. Pharmacol. 32, 56-67, doi:10.1006/rtph.2000. 1399 (2000).
4. Giorgi, M. A., Bolaños, R., Gonzalez, C. D. & Di Girolamo, G. QT interval prolongation: preclinical and clinical testing arrhythmogenesis in drugs and regulatory implications. Curr Drug Saf. 5, 54-57 (2010).
5. Farkas, A., Leprán, I. & Papp, J. G. Proarrhythmic effects of intravenous quinidine, amiodarone, D-sotalol, and almokalant in the anesthetized rabbit model of torsade de pointes. J Cardiovasc Pharmacol. 39, 287-297 (2002). (Pubitemid 34093549)
6. De Ponti, F., Poluzzi, E., Cavalli, A., Recanatini, M. & Montanaro, N. Safety of non-antiarrhythmic drugs that prolong the QT interval or induce torsade de pointes: an overview. Drug Saf. 25, 263-286 (2002). (Pubitemid 34569360)
7. Meyer, T., Leisgen, C., Gonser, B. & Gunther, E. QT-screen: high-throughput cardiac safety pharmacology by extracellular electrophysiology on primary cardiac myocytes. Assay Drug Dev Technol 2, 507-514 (2004). (Pubitemid 39619093)
8. Frothingham, R. Rates of torsades de pointes associated with ciprofloxacin, ofloxacin, levofloxacin, gatifloxacin, and moxifloxacin. Pharmacotherapy 21, 1468-1472 (2001). (Pubitemid 33117251)
9. Csete, M. Translational prospects for human induced pluripotent stem cells. Regen Med 5, 509-519 (2010).
10. Kattman, S. J., Koonce, C. H., Swanson, B. J. & Anson, B. D. Stem cells and their derivatives: a renaissance in cardiovascular translational research. J Cardiovasc Transl Res 4, 66-72 (2011).
11. Braam, S. R. et al. Prediction of drug-induced cardiotoxicity using human embryonic stem cell-derived cardiomyocytes. Stem Cell Res 4, 107-116 (2010).
12. Jonsson, M. K. B. et al. Quantified proarrhythmic potential of selected human embryonic stem cell-derived cardiomyocytes. Stem Cell Res 4, 189-200 (2010).
13. Antzelevitch, C. Drug-induced spatial dispersion of repolarization. Cardiol J 15, 100-121 (2008). (Pubitemid 351721972)
14. Bass, A. S. et al. International Life Sciences Institute (Health and Environmental Sciences Institute, HESI) initiative on moving towards better predictors of druginduced torsades de pointes. Br J Pharmacol 154, 1491-1501 (2008).
15. Kaneko, T., Kojima, K. & Yasuda, K. Dependence of the community effect of cultured cardiomyocytes on the cell network pattern. Biochem. Biophys. Res. Commun. 356, 494-498 (2007). (Pubitemid 46452573)
16. Kojima, K., Kaneko, T. & Yasuda, K. Role of the community effect of cardiomyocyte in the entrainment and reestablishment of stable beating rhythms. Biochem. Biophys. Res. Commun. 351, 209-215 (2006). (Pubitemid 44635428)
17. Yasuda, K., Kaneko, T. & Nomura, F. On-chip pre-clinical cardiac toxicity: testing compounds beyond hERG And QT using hES/hiPS cardiomyocyte re-entry cell network model on a chip. Proceeding of The 14th International Conference on Miniaturized Systems for Chemistry and Life Sciences (MicroTAS 2010) Verpoorte, S. (ed.), 716-718 (Curran Associates, New York, 2013).
18. Yasuda, K. in Lab-on-Chips for Cellomics (eds Helene, Andersson & Albert, van den Berg) Ch. Chapter 9 225-256 (Kluwer Academic Publishers, 2004).
19. Kaneko, T., Kojima, K. & Yasuda, K. An on-chip cardiomyocyte cell network assay for stable drug screening regarding community effect of cell network size. Analyst 132, 892-898 (2007). (Pubitemid 47283700)
20. Kaneko, T., Kojima, K. & Yasuda, K. in Frontiers in Life Sciences (eds Makoto, Fujiwara, Shoichi, Ishiura & Naoki, Sato) 27-38 (Research Signpost, 2006).
21. Thomsen, M. B. et al. Increased Short-Term Variability of Repolarization Predicts d-Sotalol-Induced Torsades de Pointes in Dogs. Circulation 110, 2453-2459 (2004). (Pubitemid 39407353)
22. Kitahara, Y. et al. Nateglinide stimulates glucagon-like peptide-1 release by human intestinal L cells via a K(ATP) channel-independent mechanism. Biol Pharm Bull 34, 671-676 (2011).
23. Raetz, S. L. et al. Dynamic characteristics of cardiac R-R intervals during sleep and waking states. Sleep 14, 526-533 (1991).
24. Martin, R. L. et al. The utility of hERG and repolarization assays in evaluating delayed cardiac repolarization: influence of multi-channel block. J Cardiovasc Pharmacol 43, 369-379 (2004). (Pubitemid 38270603)
25. Lawrence, C. L., Bridgland-Taylor, M. H., Pollard, C. E., Hammond, T. G. & Valentin, J. P. A rabbit Langendorff heart proarrhythmia model: predictive value for clinical identification of Torsades de Pointes. Br J Pharmacol 149, 845-860 (2006). (Pubitemid 44851709)
26. Peng, S., Lacerda, A. E., Kirsch, G. E., Brown, A. M. & Bruening-Wright, A. The action potential and comparative pharmacology of stem cell-derived human cardiomyocytes. J Pharmacol Toxicol Methods 61, 277-286 (2010).
27. Lawrence, C. L., Pollard, C. E., Hammond, T. G. & Valentin, J. P. Nonclinical proarrhythmia models: predicting Torsades de Pointes. J Pharmacol Toxicol Methods 52, 46-59 (2005). (Pubitemid 41008629)
28. Hescheler, J. et al. Determination of electrical properties of ES cell-derived cardiomyocytes using MEAs. J Electrocardiol 37 Suppl, 110-116 (2004). (Pubitemid 39452877)
29. Braam, S. R. & Mummery, C. L. Human stem cell models for predictive cardiac safety pharmacology. Stem Cell Res 4, 155-156 (2010).
30. Guo, L. et al. Estimating the Risk of Drug-Induced Proarrhythmia Using Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes. Toxicol Sci 123, 281-289 (2011).
31. Lu, H. R., Hermans, A. N. & Gallacher, D. J. Does terfenadine-induced ventricular tachycardia/fibrillation directly relate to its QT prolongation and Torsades de Pointes? Br J Pharmacol 166, 1490-1502 (2012).